Meredith M. Regan, ScD, on Early Breast Cancer: Updated Results From the TEXT and SOFT Trials
2021 San Antonio Breast Cancer Symposium
Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discusses findings that point to the potential benefits of using adjuvant exemestane plus ovarian function suppression (OFS) to treat premenopausal women with hormone receptor–positive early breast cancer. This conclusion came after 13 years of median follow-up on the TEXT and SOFT trials, during which this regimen was compared with tamoxifen and OFS (Abstract GS2-05).
The ASCO Post Staff
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses phase III findings of the PADA-1 study, which showed that optimizing endocrine therapy after detecting the ESR1 mutation in patients with hormone receptor–positive, HER2-negative metastatic breast cancer may double their median progression-free survival (Abstract GS3-05).
The ASCO Post Staff
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer. Dr. Gnant also talks about whether any correlative studies hint at patient subgroups that this regimen may benefit (Abstract GS1-07) .
The ASCO Post Staff
Banu Arun, MD, of The University of Texas MD Anderson Cancer Center, discusses a session she moderated that included discussion of how exercise and diet may reduce the risk of breast cancer, and emerging non-endocrine treatments that may help prevent the disease.
The ASCO Post Staff
Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).
The ASCO Post Staff
Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest updates from the SUMMIT trial, which explored the combinations of neratinib/fulvestrant/trastuzumab and neratinib plus trastuzumab, as well as fulvestrant alone. The combination regimens appeared to benefit patients with hormone–receptor positive, HER2-mutated metastatic breast cancer who have had prior exposure to CDK4/6 inhibitors, and those with HER2-mutated triple-negative disease (Abstract GS4-10).
